The transformation from normal to malignant urothelium is induced by certain chemical agents, pathogens, and physical stimuli. Tumor-inciting stimuli can affect the entire urinary tract from the renal calyces to the urethra, although 95% of primary urothelial tumors occur within the bladder. Patients who develop bladder cancer are considered to have a "field change" disease, suggesting that the entire urothelium is at risk for tumor formation. Recurrences in various sites and particularly within the bladder are therefore characteristic, and patients must undergo lifelong surveillance. 
Introduction
The transformation from normal to malignant urothelium is induced by certain chemical agents, pathogens, and physical stimuli. Tumor-inciting stimuli can affect the entire urinary tract from the renal calyces to the urethra, although 95% of primary urothelial tumors occur within the bladder. Patients who develop bladder cancer are considered to have a "field change" disease, suggesting that the entire urothelium is at risk for tumor formation. Recurrences in various sites and particularly within the bladder are therefore characteristic, and patients must undergo lifelong surveillance.
Epidemiology
Bladder cancer is the fourth most common cancer in men and was estimated to be the eighth leading cause of cancer-related deaths in men in 2009. 1 There is a 4:1 male:female predominance as well as a 2:1 white:black ratio. 2 Caucasian Americans have a more favorable survival by stage at presentation in part related to the higher proportion of nontransitional cell carcinomas seen in African Americans. 3 Caucasian Americans have a 2-fold increased risk of developing bladder cancer compared with African Americans. Latin Americans have an even lower risk of bladder cancer development compared with African Americans. 1 Bladder cancer is a disease of senior adults; the overall median age at diagnosis is 70 years in men and women combined. 4 The rare adolescent or the younger adult who develops a transitional cell cancer generally has a well-differentiated low-grade tumor with a better long-term prognosis. 5 
Histology
Most newly diagnosed bladder cancers (75%) are non-muscle invasive (confined to the bladder mucosa or to the lamina propria); the remaining 25% are invasive into or through the muscularis propria. 6 Approximately 90% of patients with bladder cancer have transitional cell carcinoma (TCC), whereas 5% have squamous cell carcinomas and 1% to 2% have adenocarcinomas. Smaller percentages of patients have primary small cell carcinoma of the bladder or other histological variants of TCC, including micropapillary (highly aggressive) and lymphoepithelioma-like (better prognosis than high-grade invasive TCC) tumors. Adenocarcinomas arise from the urachus or from the bladder. A partial cystectomy and pelvic lymphadenectomy should be considered for the patient with a urachal adenocarcinoma. Small cell carcinomas of the bladder are aggressive, are often associated with a poor prognosis, and should be managed with neoadjuvant etoposide and cisplatin systemic chemotherapy followed by cystectomy or localized external radiation. 7 Micropapillary variants of TCC resemble ovarian micropapillary serous carcinomas, are usually high stage and grade, are associated with lymphovascular invasion, and should be treated with early radical cystectomy even in the non-muscle invasive stage.
8 Table 1 lists the most frequently encountered malignant, premalignant, and benign lesions originating from the bladder urothelium.
Risk Factors
Known risk factors for bladder cancer include male gender, tobacco use (secondary to the chemical carcinogens 4-aminobiphenyl and o-toluidine), occupational exposure to aryl amines, ionizing radiation, and exposure to cyclo phosphamide and phenacetin-containing analgesics. 9 Suspected risk factors for bladder cancer include dietary factors, chlorination by-products in drinking water, and various occupational exposures incurred by dye, rubber, and leather workers, painters, and truck drivers. Genetic susceptibility to environmental exposures has been demonstrated in epidemiologic studies of bladder cancer, including polymorphisms in detoxifying enzymes such as N-acetyl transferase and glutathione S-transferase. 10 Approximately 8% of patients with bladder cancer report a positive family history, yet bladder cancer is thought to be nonhereditary except for the rare familial Lynch syndrome II (defect in DNA mismatch repair) where patients are at risk for the development of both colon and urothelial tumors.
Tobacco use appears to be the most identifiable risk factor for bladder cancer. Smokers (particularly greater than 40 pack-years) have up to a 4-fold increased risk for bladder cancer compared with patients who have never smoked.
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In patients who stop using tobacco, the potential lingering carcinogenic effects of tobacco take considerably longer to approach the baseline risk for developing bladder cancer in patients who never smoked compared with the reduction of risk for lung and cardiovascular disease. Nevertheless, some data suggest that smoking cessation decreases the rate of tumor recurrence. 12 Chronic cystitis and schistosoma hematobium infections are risk factors for squamous cell carcinomas as opposed to transitional cell tumors.
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Molecular Characterization
The different potential pathways for bladder cancer tumorigenesis are shown in Fig 1. Evidence suggests that the most common chromosomal abnormality is the loss of large segments of chromosome 9, especially 9q. The two proposed pathways include (1) the proliferative 
Presenting Signs and Symptoms
Microscopic or gross hematuria is the most important presenting symptom and occurs in the majority of patients with bladder cancer. Irritative lower urinary tract symptoms such as urinary frequency, urgency, and dysuria are common. The irritative symptoms are more predominant in patients with high-grade papillary tumors, CIS, or invasive disease. Mucosuria is possible in the patient with adenocarcinoma. These signs and symptoms often lead to an early diagnosis for most patients with TCC. The discovery of incidental bladder cancer at autopsies is virtually nonexistent. Thus, there appears to be little latency between the development of cancer and symptomatic onset.
Diagnostic Evaluation
Patients with hematuria or lower urinary tract symptoms should be considered for upper tract imaging with CT urography alone or with renal ultrasound combined with intravenous pyelography or retrograde pyelography. A complete urologic evaluation to detect urothelial tumors includes cystoscopy, which permits direct visualization of the entire urethra and the bladder urothelium. Complementary methods used to detect urothelial tumors include the evaluation of voided urine or bladder wash specimens for cytology and increasingly the use of laboratory-and office-based urinary biomarker assays. 
Cystoscopy
Cytology
Urine cytology remains the most specific adjunct to cystoscopy in the detection and surveillance of bladder cancer. 18 Characteristic cytologic changes include cellular and nuclear pleomorphism, increased nuclear to cytoplasmic ratio, and nuclear irregularity. 19 The diagnostic yield of cytology may be improved by bladder washes or repeated voided samples. 20 The specificity is best for patients with higher-grade tumors or CIS and has been reported to be as high as 98.3%. 21 The sensitivity of cytology for diagnosing low-grade tumors is poor, but fortunately, the progression rate for low-grade noninvasive tumors is low.
"Atypical" cytology is a nonspecific term often used to characterize the appearance of cells in urine cytology specimens, but the significance of this finding is poorly understood. Atypical cells are common in patients with urinary diversions and various conditions leading toward bladder inflammation or cystitis. If cystoscopy and uppertract evaluation are negative, atypical cells alone usually warrant no further investigation or bladder biopsies. Although the presence of "dysplastic" cells warrants follow-up, the finding is not diagnostic for a malignancy. "Suspicious" cytology indicates the need for either further investigation or careful surveillance. Nabi et al 22 observed that 35% of patients with suspicious cytology but no evidence of bladder cancer on initial evaluation subsequently developed transitional cell tumors with a mean time to diagnosis of nearly 6 months.
Biomarkers
Many biomarkers have been incorporated into strategies for the diagnosis, surveillance, and management of bladder cancer. [23] [24] [25] Although the ideal marker is unknown, several tests are currently approved for clinical use by the US Food and Drug Administration (FDA). Fluid-based, qualitative points of care assays include the NMP22 BladderChek Test (nuclear matrix protein, Matritech Inc, Newton, MA) and the BTA Stat test (bladder tumor antigen, Polymedco, Inc, Cortlandt Manor, NY). The FDA-approved cell-based assays include the ImmunoCyt test (Diagnocure Inc, Quebec City, Quebec, Canada) and the FISH analysis (fluorescence in situ hybridization, Vysis UroVysion Systems, Abbott Laboratories, Abbott Park, IL). To date, none of the approved biomarker assays eliminate the need for diagnostic or surveillance cystoscopy. Most markers continue to be used in conjunction with urine or bladder wash cytology. Sensitivity and specificity of the common urinary markers can be seen in Table 2 . Accuracy of the markers can be affected by collection technique, coexisting benign bladder pathology, and prior intravesical therapy. As an example, UroVysion is not approved by the FDA to be collected with a bladder barbotage as this can dislodge large numbers of normal urothelial cells, leading to a false-negative result. Furthermore, the BTA Stat test has a lower specificity when used for surveillance after intravesical therapy. 26 All markers should be used in conjunction with standard cytology, and no marker has yet supplanted cystoscopy as the gold standard for bladder tumor detection. 26 Multiple other markers have been studied but are not yet approved by the FDA for routine clinical application: BLCA-4, telomerase, survivin, hyaluronic acid, microsatellite analysis, cytokeritins, and Lewis x blood group antigens. 27 Similar to the FDA-approved markers, all are superior to cytology for sensitivity but inferior for specificity. Table 3 demonstrates the current TNM staging for bladder cancer. 28 Non-muscle invasive bladder cancer includes a heterogeneous group of tumors with variable biologic potential. Non-muscle invasive tumors are confined to the bladder urothelium (Ta and Tis) and to the lamina propria (T1) (Fig 2) . There is no nuclear overlapping, and the cells are not densely arranged (hematoxylin-eosin, magnification ×100). (B) Low-grade papillary urothelial carcinoma: papillae show an orderly proliferation of densely arranged cells with mild to moderate atypia without loss of polarity. There is increased cellularity without nuclear overlapping (hematoxylin-eosin, magnification ×40). (C) High-grade papillary urothelial carcinoma: papillary frond with complete architectural disorder and loss of polarity is present. There is nuclear overlapping, nuclear enlargement, and hyperchromasia (hematoxylin-eosin, magnification ×400). (D) Urothelial carcinoma invading into lamina propria: clusters of pleomorphic cells with nuclear enlargement and hyperchromasia infiltrate the underlying fibroconnective stroma (hematoxylin-eosin, magnification ×200).
Pathology and Staging
A C B D
All of the urinary excretory passages are lined by urothelium. The wall of the bladder is formed by four layers: urothelium, lamina propria, muscularis propria, and adventitia or serosa. Depending on the location, these layers may be surrounded by perivesical fat. The thickness of the urothelium and the shape of the urothelial cells vary depending on the degree of bladder distension. In an empty bladder, the urothelium can be up to seven cells thick. The most superficial or luminal layer of urothelium consists of large, sometimes binucleated cells with abundant eosinophilic cytoplasm and a rounded free surface; these are called umbrella cells. The urothelium rests on a thin basement membrane layer, which separates the urothelium from the underlying lamina propria. The lamina propria is formed of abundant connective tissue containing vascular network, lymphatic channels, sensory nerve endings, a few elastic fibers, and small fascicles of smooth muscle. The smooth muscle fascicles are present in the superficial lamina propria and may form complete or incomplete muscularis mucosa. The muscularis mucosa is distinctly separate from the underlying muscularis propria, also known as detrusor muscle. The muscularis propria has loosely anastomosing, ill-defined internal and external longitudinal layers and a middle circular layer of muscle. The bundles of muscularis propria are much larger than muscle fascicles in the muscularis mucosa. The outermost layer of the viscus is an adventitia of connective tissue; only the superior surface is covered by serosa of the pelvic peritoneum. 29 The World Health Organization/International Society of Urologic Pathology (WHO/ISUP) consensus classification of papillary urothelial lesions confined to the urothelium includes papillary hyperplasia as a distinct category having markedly thickened mucosa without cytological atypia. 30 There is no evidence suggesting that papillary hyperplasia alone has any premalignant potential.
Papillary neoplasms include urothelial papilloma, papillary urothelial neoplasm of low malignant potential (PUNLMP), low-grade papillary carcinoma, and highgrade papillary carcinoma. Urothelial papilloma is characterized by discrete papillary fronds with nonbranching or minimally branching arrangement, slender fibrovascular stalks, and a predominantly exophytic pattern. The urothelium is within normal limits of thickness, lacks atypia, and has prominent umbrella cells. Urothelial papilloma rarely recurs after complete resection.
PUNLMP is a papillary urothelial tumor that resembles the papilloma but shows increased cellular proliferation exceeding the thickness of normal urothelium. The polarity is preserved, and variation in architectural and nuclear features is either absence or minimal. The nuclei are slightly enlarged compared with normal nuclei, and mitoses are rare. The umbrella cell layer is preserved.
In contrast to papilloma and PUNLMP, low-grade papillary carcinoma has papillary fronds with frequent branching and an orderly appearance, but with easily recognizable variations in nuclear polarity, size, shape, and chromatin pattern. Inconspicuous nucleoli may be present and mitotic figures are infrequent. Contrary to the orderly appearance of low-grade carcinoma, the high-grade papillary carcinoma has a predominant pattern of disorder with moderate to marked architectural and cytological atypia. High-grade tumors have fused papillae with variable thickness, frequent cell dyscohesion, frequent mitoses, and marked variation in nuclear features with prominent nucleoli. The neoplastic cells of papillary carcinomas invade the bladder wall as nests, cords, trabeculae, small clusters, or single cells that are often separated by desmoplastic stroma. Invasion of muscularis mucosa within the lamina propria must be clearly distinguished from invasion of muscularis propria. This distinction is critical in that muscularis propria invasion (T2+) often dictates the need for more aggressive management including systemic chemotherapy and cystectomy.
CIS is a nonpapillary flat lesion in which the surface epithelium contains cells that are cytologically malignant. The nuclear anaplasia observed in CIS is identical to high-grade urothelial carcinoma. Mitoses are common, and there is loss of cell polarity with irregular nuclear crowding. The neoplastic changes may or may not involve the entire thickness of the urothelium. Individual neoplastic cells may be seen scattered among normal-appearing urothelial cells; this is termed pagetoid spread. CIS is commonly multifocal and may be diffuse.
Transurethral Resection
Transurethral resection of the bladder tumor (TURBT) is the first step in the initial management of bladder cancer. A TURBT is both diagnostic and therapeutic, and the procedure provides critical staging information. In the setting of a TURBT, the configuration (flat, sessile, or papillary), location (trigone, base, dome, or lateral walls), size (centimeters), and number of tumors should be noted. Tumors are completely resected, and other than for superficial appearing low-grade tumors, muscularis propria must be included in the specimen to ensure adequate resection, thorough histological evaluation, and accurate clinical staging. Management might include directed bladder biopsies of abnormalappearing urothelium or biopsies of the prostatic urethra to exclude "protected sanctuaries" of cancer such as CIS. Biopsy or resection of the prostatic urethra also should be considered if the patient has tumor at the bladder neck or if tumor is within the prostatic urethra. Random biopsies of normal-appearing bladder urothelium may or may not alter the management of the bladder malignancy, and as such, this practice remains controversial except when contemplating a partial cystectomy or other bladder-sparing approaches to rule out coincident CIS or when the cytology is positive and yet the tumor appears papillary and noninvasive. 31, 32 Immediately before and following tumor resection, an examination under anesthesia is performed. Bladder pedicle thickening or a palpable three-dimensional mass suggests the possibility of muscle invasive disease or a more locally advanced bladder malignancy. If locally advanced disease is evident, attention should be given to the mobility of the bladder and the adjacent pelvic viscera.
There are several reasons for considering a restaging resection in patients with high-risk non-muscle invasive bladder cancer (ie, large-volume cTa or cT1 disease). First, the repeat resection ensures adequate evaluation of the muscularis propria while detecting and treating persistent tumor in approximately 75% of patients. Under such circumstances, retrospective data suggest that the restaging transurethral resection improves the initial response rate to intravesical bacille Calmette-Guérin (BCG) therapy, reduces the frequency of subsequent tumor recurrence, and appears to delay early tumor progression. 33 Secondly, a re-resection results in clinical upstaging to muscle invasive tumor in up to 30% of patients. 34 Finally, patients with persistent high-grade cT1 tumors on repeat resection are at high risk for early progression to muscle-invasive disease and thus might be appropriate candidates for early cystectomy. 35 The restaging transurethral resection of the tumor bed is typically performed within 1 to 4 weeks following the initial TURBT. While highly recommended for most if not all patients with tumor invasion of the lamina propria, the restaging resection is imperative and recognized as the standard of care for patients with cT1 tumors when adequate sampling of the muscularis propria is not represented in the histological specimen. 36 Complications resulting from TURBT include irritative lower urinary tract symptoms, bleeding, bladder perforation, urethral stricturing, and scarring of the ureteral orifices that could potentially lead to renal obstruction. Extensive resection or persistent bleeding requires placement of a Foley catheter postresection and continuous irrigation. Most patients who suffer an extraperitoneal bladder perforation are managed conservatively. Conversely, most patients with intraperitoneal bladder perforations are managed with exploratory laparotomy and primary repair, particularly if the perforation is large and is associated with persistent peritonitis, excessive bleeding, or the rare finding of a bowel injury. Some investigators acknowledge a higher risk of extravesical bladder cancer seeding when patients with intraperitoneal ruptures from TURBT were managed with laparotomy and primary bladder repair compared with those managed conservatively with prolonged catheter drainage and/or percutaneous drain placement. 37, 38 Thus, the decision to repair a bladder perforation should be based on individual patient circumstances and careful scrutiny of the clinical findings to optimize recovery and oncologic outcome.
Risk Group Classification
The combination of cystoscopic and pathologic findings determines the need for intravesical therapy and predicts the risk for cancer recurrence, progression, and cancer-related mortality. 39 Using standard clinical and pathologic criteria, researchers from the European Organisation for Research and Treatment of Cancer (EORTC) developed a scoring system based on the six most significant risk factors for recurrence and progression. The risk factors were determined from a database containing 2,596 patients with Ta or T1 tumors (from seven randomized trials) who had undergone a TURBT yet were not managed with re-resections or maintenance intravesical BCG therapy. The six predictors included number of tumors, tumor diameter, prior recurrence rate, clinical T stage, the presence of concomitant CIS, and the tumor grade (Table 4) . 40, 41 Evident from these data is that regardless of risk group stratification, a large percentage of patients with non-muscle invasive cancer will recur (Table 5) . 40 Furthermore, the presence of recurrent tumor at the initial 3-month surveillance cystoscopy is strongly predictive of continued tumor recurrences. Patients with grade 3 tumors and CIS (especially in association with lamina propria invasion) harbor the highest risk for disease progression. 
Intravesical Therapy
An important strategy in the management of non-muscle invasive bladder cancer includes the use of intra vesical therapies to treat microscopic tumor persistence and to prevent tumor reimplantation, new tumor formation, and possibly tumor grade and stage progression. Intravesical chemotherapeutic and immunomodulatory agents most commonly utilized in the United States are listed in Table 6 .
Immediate Postresection Intravesical Therapy
There are several reasons to support consideration of immediate postresection intravesical chemotherapy.
Half of all tumor recurrences may be due to the TURBT and the mechanical dispursement of tumor cells with resultant tumor reimplantation at sites of resection. Animal models support this theory, confirming the ease of tumor reimplantation onto traumatized urothelial surfaces. 42 Additionally, most synchronous and metachronous tumors appear to be of clonal origin. 43 Two peaks of tumor relapse are evident. An early peak is likely due to tumor recurrence or persistence, whereas a late peak is likely due to a second primary tumor. Only the early peak of tumor relapse is affected by the immediate postresection instillation of an intravesical agent. Available agents include mitomycin C, thiotepa, and doxorubicin. In the United States, mitomycin C (20 to 40 mg in 20 to 40 mL of sterile water) has been the most widely utilized agent in the immediate postresection setting. Dwell time within the bladder ranges from 30 to 60 minutes. A therapeutic benefit from a single one-time instillation of mitomycin C could be achieved up to 24 hours following the TURBT, although the most desirable time to instill the therapy may be within the first 2 to 6 hours following resection. 40 Mitomycin C and other immediate postresection intravesical therapies should be withheld in cases of suspected perforation, significant large-volume resections, or significant gross hematuria requiring either hand irrigation or continuous bladder irrigation with sterile saline to keep the urinary effluent clear. Immunomodulatory agents such as BCG or interferon are never used in the immediate postresection setting.
Published meta-analysis data support the immediate postresection instillation of chemotherapy following TURBT. Sylvester et al 44 reviewed data from seven randomized trials with tumor recurrence information on 1,476 patients. Intravesical agents included mitomycin C, thiotepa, epirubicin, and pirarubicin (epirubicin and pirarubicin are not available in the United States for this application). In all studies, the instillation was administered within 24 hours. Patients in the treatment group experienced a 39% decrease in the odds of recurrence compared with patients managed with observation alone following TURBT. Recurrence-free percentages were better for patients with single tumors compared 
Immunotherapies
Mechanism of Action
Bacille Calmette-Guérin T-helper type I immune response (increased interleukin-2 and interferon gamma)
Interferon * Lymphocyte activation, potentiates T-helper type I response (inhibits production of interleukin-10, an inhibitory cytokine); antiangiogenic; antiproliferative * Used in combination with bacille Calmette-Guérin.
to patients with multiple tumors. Presently, the European Association of Urology (EAU) recommends immediate postresection therapy for all patients undergoing a complete, uneventful TURBT. 40 The American Urological Association (AUA) guidelines recommend postresection therapy when there is a suspected recurrence of low-grade, noninvasive bladder cancer. However, this recommendation is described as an option in cases where stage and grade are not known, citing concerns about cost, uncertain pathology, side effects, and the lack of efficacy for muscle invasive tumors.
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Induction Intravesical Therapy Generally, accepted criteria for induction intravesical therapy following TURBT include the presence of highgrade tumors, T1 tumors, CIS, tumor multifocality (Ն 3 tumors), large-volume tumors, and tumor recurrence. Induction therapy is defined as a weekly administration of an intravesical agent for at least 6 consecutive weeks. Therapy is initiated approximately 2 to 4 weeks following the patient's TURBT. For low-grade, larger-volume tumors, there is no clear superiority of an induction course of any particular intravesical chemotherapy (eg, mitomycin C) or of BCG over other therapies. The AUA guideline panel members recommend that an induction course of either intravesical chemotherapy or BCG should be administered for the treatment of non-muscle invasive bladder cancers that have an increased risk of recurrence but a low risk of progression. 36 For patients with high-risk tumors (high-grade Ta, high-grade T1, CIS, or a combination thereof), the recommended therapy is induction BCG followed by maintenance BCG. This has been consistently shown to be superior to intravesical chemotherapy for preventing tumor recurrences. BCG is an inactivated form of mycobacterium tuberculosis and has been shown to induce a cellular and cytokine-induced antiangiogenic environment that aids in inhibiting future tumor growth and progression. 45 BCG is the foundation of intravesical therapy for intermediate-and high-risk tumors. The AUA panel's single-arm meta-analysis of high-risk patients revealed an estimated 5-year recurrence rate of 34% in patients treated with BCG + maintenance compared with 62% in patients treated with mitomycin C + maintenance. Furthermore, the AUA meta-analysis of all risk groups revealed that compared to TURBT + mitomycin C maintenance, TURBT + BCG maintenance decreased tumor recurrences by 17% and decreased tumor progression by 5%.
Maintenance Intravesical Therapy
Maintenance therapy is defined as the periodic continued exposure of the urothelium to an intravesical agent following the achievement of a complete response to an initial induction course of intravesical therapy. Maintenance therapy following initial induction therapy is an important strategy for decreasing tumor recurrence and potentially decreasing tumor progression. The 5-year progression rates for high-risk tumors range from 15% to 50% (highest for multifocal high-grade T1 + CIS). In the high-risk setting, intravesical BCG significantly reduces the risk of recurrence and progression after transurethral resection in patients with non-muscle invasive bladder cancer who receive maintenance BCG therapy. 46 The best level evidence for maintenance BCG therapy comes from a trial of the Southwest Oncology Group (SWOG 8507). 47 Patients with highrisk TCC who were BCG responders were randomized to 3 weekly maintenance courses at 3, 6, and 12 months and every 6 months out to 3 years. Only 16% of patients completed 36 months of therapy, mostly related to BCG toxicity. The 5-year recurrence-free survival rate was 60% in the maintenance arm compared with 41% in the no-maintenance arm (P Ͻ .0001). The 5-year progression-free survival rate was 76% in the maintenance arm compared with 70% in the no-maintenance arm (P = .04). This trial also provided the best evidence for a maintenance schedule that is most widely incorporated into clinical practice. 47 The 5-year progression rates with low-risk tumors (low-grade, solitary, Ta) and intermediate-risk tumors (recurrent Ta/T1 low-grade, multifocal Ta/T1 low-grade) are Ͻ 5% and Ͻ 15%, respectively. 40 To date, maintenance therapy (chemotherapy or BCG) in these risk groups has not impacted progression rates due to the overall low number of observed (progression) events. In patients with low-grade tumors, maintenance intravesical chemotherapy (eg, mitomycin C) administered monthly for 3 to 12 months may impact tumor recurrences, although there are no clear data regarding the duration of therapy.
BCG Failures and Salvage Intravesical Therapy
Patients who fail BCG should be categorized into more specific groups in order to provide a more uniform definition of BCG failure. BCG-refractory patients fail to achieve a disease-free state by 6 months after initial BCG therapy with either maintenance or re-treatment at 3 months because of either persistent or rapidly recurrent tumor. The BCG-refractory category also includes any progression in stage, grade, or disease extent after the first cycle of BCG. Patients with BCGresistant disease have recurrent or persistent tumor at 3 months following an induction cycle but of lesser degree, stage, or grade that subsequently is no longer present at 6 months. Essentially, the disease improves and then resolves with further BCG therapy. Patients with BCG-relapsing disease have recurrent tumor following a disease-free period of at least 6 months. Finally, BCG-intolerant patients include those whose disease recurs after a less-than-adequate course of therapy because of a serious adverse event or symptomatic intolerance that mandates discontinuation of further BCG therapy. 48, 49 Patients who fail an initial induction course of intravesical chemotherapy respond to intravesical BCG at a similar rate as treatment-naive patients. On the contrary, patients with BCG refractory disease seldom respond to salvage intravesical chemotherapy. Following initial BCG induction failure, 30% to 50% of patients will respond to a second induction course of BCG. High-risk patients who fail two induction courses of BCG should be considered BCG-refractory 50 and offered cystectomy (an AUA guideline recommendation) since Ͻ 20% of patients respond to continued attempts to eradicate tumor utilizing BCG. 36 Several other salvage regimens have been studied in patients who are BCG-refractory or BCG-intolerant. Intravesical interferon monotherapy results in a 2-year disease-free survival rate of less than 15% in patients who fail BCG therapy. 51 However, in combination with low-dose BCG, the 2-year disease-free survival rate is 40% to 50% in patients who failed prior BCG induction (± maintenance BCG) or were BCG-intolerant. 52, 53 Valrubicin (a semisynthetic derivative of the anthracycline antibiotic doxorubicin) is approved by the FDA for the treatment of BCG-refractory CIS of the bladder for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. 54 Gem citabine and docetaxel are additional investigational chemotherapeutic agents that are being studied in the BCG-failure population of patients. [55] [56] [57] Both have acceptable toxicity, but the usefulness for BCG-refractory patients is unclear until additional prospective trials have been completed. Table 7 details the toxicities most commonly associated with the use of different intravesical therapies. 36, 58 BCGrelated side effects dominate the toxicity profile, largely due to the more frequent use and administration of BCG. BCG toxicity can be subdivided into different grades of severity. Accordingly, higher grades result in the need for more intense evaluation and management (Table 8 ). The irritative lower urinary tract symptoms mostly attributed to non-infectious (inflammatory) cystitis are the most frequently reported side effects. Several maneuvers are employed to treat the BCG-related symptoms; these include administering anticholinergic agents, reducing BCG dose (half, one-third, one-tenth strength BCG administration), decreasing dwell time (at least 30 minutes dwell may be as effective as 1 to 2 hours), utilizing antibiotics (ofloxacin 8 and 20 hours following BCG instillation), and spacing treatments from weekly to every 2 weeks. 59, 60 Antibiotic use, especially quinolones, can theoretically decrease BCG viability, but this has not yet been shown clinically. 61 For grade II BCG infections, therapy should be discontinued and consideration given to hospitalization with initiation of intravenous antibiotics, isoniazid, and pyridoxine. In the patient with grade III toxicity, including suspected BCG sepsis, therapy would also include rifampin, ethambutol, fluoroquinolones, and intravenous corticosteroids.
Complications of Intravesical Therapy
Follow-Up
The high rate and frequency of recurrence and the concern for disease progression -especially in patients with high-risk tumors -mandate careful strategies for tumor surveillance. Cytology and commercially available biomarkers do not obviate the need for cystoscopy. The schema most commonly adopted for high-risk patients includes assessment with cystoscopy and cytology every 3 months for 2 years, then every 6 months for 2 years, and then annually. In the lowrisk patient, if the initial 3-month cystoscopy following TURBT appears normal, it is acceptable to consider earlier initiation of every 6-to 12-month cystoscopy and cytology. Bladder biopsies should be performed to assess suspicious mucosal lesions and to evaluate treatment response for patients with CIS, and also if the cytology becomes posi- 
Cystectomy
Several strong indications point to recommending early cystectomy in patients with non-muscle invasive bladder cancer: unfavorable histology (micropapillary, adenocarcinoma, squamous cell carcinoma), lymphovascular invasion in patients with clinical stage T1 tumor, incomplete resection of multifocal T1 highgrade tumor, BCG induction failure in patients with T1 high-grade tumors or CIS, deep prostatic ductal involvement with TCC, and the bladder-crippled patient with significant lower urinary tract symptoms and recurrent tumor. 8, 36, 48, 62 The AUA considers early cystectomy as an option for patients with any high-grade Ta/T1 tumor or CIS at initial presentation dependent on the volume of disease, the completeness of resection, and a discussion of the potential risks and benefits associated with intravesical therapy. 36 Prolonged attempts to treat patients with high-risk tumors using ineffective intravesical therapies might lead to local or even distant disease progression. Overall and disease-specific survival is more favorable for patients with organ-confined tumors (Յ T2) at the time of cystectomy compared to patients with extravesical or node-positive disease (Ͼ T2 or N+).
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Conclusions
Bladder cancer recurrence and progression are dependent on multiple clinical and pathologic features as well as successful macro-and microablation using traditional endoscopic surgical techniques and intravesical therapies, respectively. Urine cytology remains the most specific test for detecting de novo or recurrent transitional cell tumors. Compared to cytology, several fluid-based and cell-based urinary assays maintain superior sensitivity for cancer detection, yet no marker is as valuable as cystoscopy for bladder cancer diagnosis and surveillance. Intravesical chemotherapeutic and immunotherapeutic agents prolong recurrence-free survival, and BCG therapy in particular may positively alter rates of cancer progression when combined with 
